Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT04003974 is registered in ClinicalTrials.gov with Fulcrum Therapeutics as lead sponsor.

NCT NCT04003974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04003974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Lead sponsor
Fulcrum Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2019
Completion date
January 28, 2021
Enrollment
80 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

facioscapulohumeral muscular dystrophy (fshd)